Contents

Search

belatacept (Nulojix)

Indications: - renal transplantation - prophylaxis of renal graft rejection (adults) - for use in combination with basiliximab induction, mycophenolate mofetil, & corticosteroids - for use only in renal transplant patients who are Epstein-Barr virus (EBV) seropositive Contraindications: - use in liver transplant patients is not recommended due to an increased risk of graft loss & death Adverse effects: - increased risk of a) post-transplant lymphoproliferative disorder, predominantly involving the central nervous system b) progressive multifocal leukoencephalopathy Mechanism of action: - selective T-cell costimulation blocker

Interactions

drug adverse effects of immunosuppressive agents monitor with immunosuppressive agents

General

immunosuppressive agent

References

  1. FDA MedWatch: 07/07/2011 Nulojix (belatacept): Risk Evaluation and Mitigation Strategy (REMS) Increased Risk of Post-transplant Lymphoproliferative Disorder (PTLD), predominantly involving the Central Nervous System (CNS), and Progressive Multifocal Leukoencephalopathy (PML)
  2. Deprecated Reference